Welcome to our dedicated page for Bioxcel Therapeutics news (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on Bioxcel Therapeutics stock.
BioXcel Therapeutics develops AI-enabled biopharmaceutical programs in neuroscience and, through its wholly owned OnkosXcel Therapeutics subsidiary, immuno-oncology. Its news centers on IGALMI, the FDA-approved sublingual film formulation of dexmedetomidine for acute agitation associated with schizophrenia or bipolar I or II disorder in adults, and on BXCL501 development across additional neuropsychiatric settings.
Recurring updates include FDA interactions and label-expansion activity for IGALMI, commercial planning for broader use settings, financial results, and capital-raising transactions. Company announcements also cover investigator-led and funded studies of BXCL501 in areas such as acute agitation in Alzheimer’s dementia, opioid withdrawal, and acute stress reactions, alongside disclosures tied to its drug re-innovation approach using big data and machine learning.
BioXcel Therapeutics (BTAI) has appointed Will Kane as Executive Vice President and Chief Commercial Officer. With over 30 years of experience, Kane previously led Allergan's U.S. General Medicine unit, overseeing significant sales and numerous successful drug launches. His expertise will support BTI's transition from a research-focused company to a commercial entity, particularly in advancing BXCL501, a treatment for acute agitation linked to neuropsychological disorders. The pivotal SERENITY trials are imminent, with potential positive outcomes that could enhance the company's market position.
BioXcel Therapeutics, Inc. (BTAI) announced that Dr. Vimal Mehta will participate in fireside chats at two virtual investor conferences. The first event, the BMO 2020 Prescriptions for Success Healthcare Conference, will take place on June 23, 2020, at 8:30 AM ET. The second event, the BofA Securities Napa Biopharma Conference, is scheduled for June 24, 2020, at 7:30 AM PT (10:30 AM ET). Live webcasts will be available on the company’s website, with archives accessible for at least 30 days.
BioXcel Therapeutics (BTAI) has enrolled the first patient in the Phase 1b/2 RELEASE trial evaluating BXCL501, a sublingual formulation of dexmedetomidine designed to treat opioid withdrawal symptoms. This trial signifies a key advancement in BTI's neuroscience program, targeting a major health crisis exacerbated by the COVID-19 pandemic. The multicenter study aims to assess BXCL501's safety and efficacy in about 125 participants over 10 days. Preliminary data from prior studies show promise, with topline results expected in Q1 2021.
BioXcel Therapeutics, Inc. (BTAI) announced that Dr. Vimal Mehta, the Founder and CEO, will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 3:30 PM ET. The event will showcase the company's innovative use of artificial intelligence in developing therapies aimed at neuroscience and immuno-oncology. A live webcast of the presentation will be available on the company's website, with an archive accessible for 30 days post-event. BioXcel is known for its drug re-innovation approach, focusing on advanced clinical programs like BXCL501 and BXCL701.
BioXcel Therapeutics (BTAI) announced a conference call scheduled for May 12, 2020, at 8:30 AM ET, to discuss its Q1 2020 operating and financial results. The call will provide insights into the company’s performance in the clinical-stage biopharmaceutical sector, focusing on AI-driven therapy development in neuroscience and immuno-oncology. The company is known for its advanced programs, including BXCL501 for neuropsychiatric agitation and BXCL701 for rare prostate cancer and pancreatic cancer treatments.